ClinicalTrials.gg
CompletedNCT00737568Updated Mar 11, 2016Results posted

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

A Phase 3 interventional study of TDF and FTC/TDF in Hepatitis B, sponsored by Gilead Sciences. Completed at 71 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-11.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
11th of 50
280 · median 117
Started
2008
with 6 others
Phase 3
13 of 50
none open now
Registered
12th of 50
by date
Lead sponsor
8 of 50
Gilead Sciences

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 11th largest by enrollment, is one of 7 that started in 2008, is one of 13 in phase 3, and was the 12th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

The aim of therapy for the treatment of chronic hepatitis B virus (HBV) is to maintain suppression of viral replication to prevent the emergence of complications, which requires long-term therapy. Durable suppression of viral replication is achieved in the treatment of chronic viral diseases by preventing of the emergence of drug-resistant mutations. The clinical guidelines for the management of lamivudine resistant patients are variable. Some recommend switching to another agent without cross-resistance, while others recommend adding on another agent without cross-resistance. Limited clinical data exists to demonstrate whether tenofovir disoproxil fumarate (tenofovir DF; TDF) is an effective monotherapy for lamivudine resistant patients or if it should be used as part of a combination therapy regimen.

This study is designed to evaluate the effectiveness, safety, and tolerability of tenofovir DF monotherapy versus emtricitabine (FTC)/tenofovir DF combination therapy in participants with chronic HBV with lamivudine resistance (presence of the rtM204I/V mutation with or without the rtL180M mutation) over a 240-week period. Participants in this study must be receiving lamivudine treatment at the time of enrollment.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Tenofovir DF
  • Emtricitabine
  • Chronic hepatitis B
  • Combination therapy
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 280 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic infection, defined as positive serum HBsAg for at least 6 months
  • 18 through 75 years of age, inclusive
  • HBV DNA ≥ 10\^3 IU/mL
  • Receiving treatment with lamivudine with confirmation of HBV reverse transcriptase mutation(s) known to confer resistance to lamivudine (rtM204I/V with or without rtL180M) by central laboratory assessment prior to randomization; adefovir dipivoxil treatment of ≤ 48 weeks at the time of screening (inclusive of combination adefovir dipivoxil + lamivudine at entry) was allowed
  • Willing and able to provide written
  • Negative serum pregnancy test (for females of only)
  • Calculated ≥ 50 mL/min
  • ≥ 10 g/dL
  • Neutrophils ≥ 1000 /mm\^3
  • No prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other agents for HBV infection other than lamivudine or adefovir dipivoxil

Exclusion criteria

Exclusion Criteria

  • Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study
  • Males and females of who are not willing to use an effective method of during the study
  • (ALT) ≥ 10 × the (ULN)
  • Decompensated liver disease
  • Interferon or pegylated interferon therapy within 6 months of the screening visit
  • Alpha fetoprotein > 50 ng/mL
  • Evidence of hepatocellular carcinoma
  • Coinfection with virus, , or hepatitis D virus
  • Significant renal, cardiovascular, pulmonary, or neurological disease
  • Received solid organ or bone marrow transplantation
  • Receiving therapy with immunomodulators (eg, , etc.), agents, nephrotoxic agents, or agents susceptible of modifying renal excretion
  • Proximal tubulopathy
  • Known to the study drugs, the metabolites or formulation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    Tenofovir DF

    TDF plus placebo to match FTC/TDF

    Drug: TDF · Drug: FTC/TDF Placebo

  • Experimental
    FTC/TDF

    FTC/TDF plus placebo to match TDF

    Drug: FTC/TDF · Drug: TDF Placebo

Interventions

  • DrugTDF

    Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily

    Also known as: Viread®

  • DrugFTC/TDF

    Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily

    Also known as: Truvada®

  • DrugTDF Placebo

    TDF placebo tablet administered orally once daily

  • DrugFTC/TDF Placebo

    FTC/TDF placebo tablet administered orally once daily

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96

    Time frame: Week 96

Secondary outcomes

  1. Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240

    Time frame: Weeks 48, 144, 192, and 240

  2. Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240

    Time frame: Weeks 48, 96, 144, 192, and 240

  3. HBV DNA Level at Weeks 48, 96, 144, 192, and 240

    Time frame: Weeks 48, 96, 144, 192, and 240

  4. Percentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240

    Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.

    Time frame: Weeks 48, 96, 144, 192, and 240

  5. Percentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240

    The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

  6. Percentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240

    The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

  7. Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240

    The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

  8. Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240

    The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

  9. Percentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240

    The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being \< 400 copies/mL.

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

  10. Percent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240

    BMD is calculated as grams per cubic centimeter (g/cm\^2); the mean (SD) percentage change is presented.

    Time frame: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240

  11. Percent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240

    BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.

    Time frame: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240

  12. Development of Drug-resistant Mutations (DRMs)

    The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs.

    Time frame: Baseline to Week 240

08

Results

Posted Apr 11, 2013
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in North America, Europe, and New Zealand. The first participant was screened on 30 September 2008. The last study visit occurred on 09 February 2015.

Treatment Period Through Week 240
Participant flow — Treatment Period Through Week 240
MilestoneTenofovir DFFTC/Tenofovir DF
Started141139
Completed121118
Not completed2021
Withdrew: Investigator's discretion65
Withdrew: Withdrew consent56
Withdrew: Safety, tolerability, or efficacy reason34
Withdrew: Lost to follow-up33
Withdrew: Protocol violation23
Withdrew: Study discontinued by sponsor10
Treatment-Free Follow-up (TFFU) Period
Participant flow — Treatment-Free Follow-up (TFFU) Period
MilestoneTenofovir DFFTC/Tenofovir DF
Started3837
Completed1219
Not completed2618
Withdrew: Started commercial therapy2517
Withdrew: Death01
Withdrew: Withdrew consent10

Outcome measures

PrimaryPercentage of Participants With HBV DNA < 400 Copies/mL at Week 96
Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96
percentage of participantsTenofovir DFFTC/Tenofovir DF
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 9689.486.3
Statistical analysis
  • Tenofovir DF vs FTC/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.43 (The p-value for the two-sided Cochran-Mantel-Haenszel test was controlled for strata (HBeAg status and ALT level).)
SecondaryPercentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240
Time frame:
Weeks 48, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 4881.684.2
Week 14487.284.9
Week 19286.585.6
Week 24083.082.7
SecondaryPercentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240
Time frame:
Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 4876.677.7
Week 9685.883.5
Week 14486.584.9
Week 19285.184.2
Week 24081.682.0
SecondaryHBV DNA Level at Weeks 48, 96, 144, 192, and 240
Time frame:
Weeks 48, 96, 144, 192, and 240
Reported as:
Mean · log10 copies/mL
HBV DNA Level at Weeks 48, 96, 144, 192, and 240
log10 copies/mLTenofovir DFFTC/Tenofovir DF
Week 48 (TDF: n=130; FTC/TDF: n=133)2.42 ± 0.5422.48 ± 0.887
Week 96 (TDF: n=132; FTC/TDF: n=127)2.29 ± 0.2542.28 ± 0.241
Week 144 (TDF: n=128; FTC/TDF: n=123)2.26 ± 0.1732.29 ± 0.541
Week 192 (TDF: n=126; FTC/TDF: n=119)2.25 ± 0.1352.23 ± 0.027
Week 240 (TDF: n=118; FTC/TDF: n=116)2.23 ± 0.0522.26 ± 0.376
SecondaryPercentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240

Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \< 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.

Time frame:
Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 4867.469.8
Week 9670.269.8
Week 14470.275.5
Week 19275.976.3
Week 24071.671.9
SecondaryPercentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240

The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.

Time frame:
Baseline; Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 489.25.9
Week 9615.413.2
Week 14423.117.6
Week 19221.514.7
Week 24024.619.1
SecondaryPercentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240

The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.

Time frame:
Baseline; Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 486.24.4
Week 9610.810.3
Week 14412.311.8
Week 19210.810.3
Week 24012.310.3
SecondaryPercentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240

The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.

Time frame:
Baseline; Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 480.00.7
Week 960.00.7
Week 1440.71.4
Week 1920.72.9
Week 2401.42.9
SecondaryPercentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240

The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.

Time frame:
Baseline; Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 480.00.0
Week 960.00.0
Week 1440.00.7
Week 1920.00.7
Week 2400.00.7
SecondaryPercentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240

The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being \< 400 copies/mL.

Time frame:
Baseline; Weeks 48, 96, 144, 192, and 240
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240
percentage of participantsTenofovir DFFTC/Tenofovir DF
Week 48 (TDF: n=130; FTC/TDF: n=133)0.00.8
Week 96 (TDF: n=132; FTC/TDF: n=127)0.00.0
Week 144 (TDF: n=128; FTC/TDF: n=123)0.80.8
Week 192 (TDF: n=126; FTC/TDF: n=119)0.80.0
Week 240 (TDF: n=118; FTC/TDF: n=116)0.00.0
SecondaryPercent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240

BMD is calculated as grams per cubic centimeter (g/cm\^2); the mean (SD) percentage change is presented.

Time frame:
Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240
Reported as:
Mean · percentage change
Percent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240
percentage changeTenofovir DFFTC/Tenofovir DF
% Change at Week 24 (TDF: n=132; FTC/TDF: n=127)-1.74 ± 2.867-1.83 ± 2.565
% Change at Week 48 (TDF: n=126; FTC/TDF: n=121)-1.68 ± 3.094-1.73 ± 2.944
% Change at Week 72 (TDF: n=123; FTC/TDF: n=119)-1.35 ± 3.337-1.95 ± 2.977
% Change at Week 96 (TDF: n=126; FTC/TDF: n=114)-1.24 ± 3.761-1.72 ± 3.269
% Change at Week 144 (TDF: n=123; FTC/TDF: n=110)-1.36 ± 3.810-1.63 ± 3.591
% Change at Week 192 (TDF: n=120; FTC/TDF: n=106)-1.32 ± 4.237-1.60 ± 4.628
% Change at Week 240 (TDF: n=115; FTC/TDF: n=102)-0.83 ± 4.490-1.15 ± 5.130
SecondaryPercent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240

BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.

Time frame:
Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240
Reported as:
Mean · percentage change
Percent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240
percentage changeTenofovir DFFTC/Tenofovir DF
% Change at Week 24 (TDF: n=130; FTC/TDF: n=127)-0.71 ± 1.724-0.59 ± 1.835
% Change at Week 48 (TDF: n=126; FTC/TDF: n=118)-1.15 ± 2.120-1.00 ± 2.063
% Change at Week 72 (TDF: n=121; FTC/TDF: n=115)-1.59 ± 2.507-1.61 ± 2.525
% Change at Week 96 (TDF: n=125; FTC/TDF: n=112)-1.70 ± 2.617-1.77 ± 2.801
% Change at Week 144 (TDF: n=120; FTC/TDF: n=107)-2.02 ± 3.030-1.91 ± 3.281
% Change at Week 192 (TDF: n=116; FTC/TDF: n=105)-2.33 ± 3.190-2.41 ± 3.783
% Change at Week 240 (TDF: n=111; FTC/TDF: n=100)-2.46 ± 3.191-2.63 ± 3.872
SecondaryDevelopment of Drug-resistant Mutations (DRMs)

The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs.

Time frame:
Baseline to Week 240
Reported as:
Number · participants
Development of Drug-resistant Mutations (DRMs)
participantsTenofovir DFFTC/Tenofovir DF
New tenofovir DF DRMs00
Enrichment of tenofovir DF DRMs00
New FTC DRMs00
Enrichment of FTC DRMs01

Adverse events

Collected over Baseline through end of study drug treatment (average exposure 220 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir DF—23/141 (16.3%)109/141 (77.3%)
FTC/Tenofovir DF—21/139 (15.1%)105/139 (75.5%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventTenofovir DFFTC/Tenofovir DF
Alanine aminotransferase increasedInvestigations1/1413/139
OsteoarthritisMusculoskeletal and connective tissue disorders0/1412/139
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1411/139
HaematuriaRenal and urinary disorders2/1410/139
Coronary artery stenosisCardiac disorders0/1411/139
Middle ear inflammationEar and labyrinth disorders0/1411/139
Tympanic membrane perforationEar and labyrinth disorders0/1411/139
Abdominal painGastrointestinal disorders0/1411/139
DiarrhoeaGastrointestinal disorders0/1411/139
GastritisGastrointestinal disorders1/1411/139
Most frequent other events
Showing 10 of 21
Most frequent other events
EventTenofovir DFFTC/Tenofovir DF
NasopharyngitisInfections and infestations24/14120/139
HeadacheNervous system disorders23/14120/139
ArthralgiaMusculoskeletal and connective tissue disorders10/14118/139
FatigueGeneral disorders14/14115/139
Back painMusculoskeletal and connective tissue disorders10/14115/139
InfluenzaInfections and infestations14/14110/139
CoughRespiratory, thoracic and mediastinal disorders12/14113/139
DiarrhoeaGastrointestinal disorders13/1417/139
Abdominal pain upperGastrointestinal disorders8/14112/139
NauseaGastrointestinal disorders12/14111/139

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tenofovir DFFTC/Tenofovir DFTotal
Mean47.1 ± 13.6346.3 ± 13.5646.7 ± 13.58
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir DFFTC/Tenofovir DFTotal
Female373269
Male104107211
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tenofovir DFFTC/Tenofovir DFTotal
Hispanic or Latino213
Not Hispanic or Latino138137275
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Tenofovir DFFTC/Tenofovir DFTotal
Asian524294
Black or African American314
Native Hawaiian or Other Pacific Islander033
White8389172
Other347
Region of Enrollment
Region of Enrollment(participants)Tenofovir DFFTC/Tenofovir DFTotal
Austria235
Bulgaria257
Canada474390
Czech Republic9716
Germany202
Greece213
Hungary437
New Zealand71017
Poland131932
Romania171431
Serbia171936
Spain112
Turkey151328
United States314
ALT Normal at Baseline
ALT Normal at Baseline(participants)Tenofovir DFFTC/Tenofovir DFTotal
Abnormal7983162
Normal6256118
Hepatitis B Virus (HBV) DNA Level at Baseline
Hepatitis B Virus (HBV) DNA Level at Baseline(log_10 copies/mL)Tenofovir DFFTC/Tenofovir DFTotal
Mean6.40 ± 1.8266.53 ± 1.9686.46 ± 1.896
HBV e Antigen (HBeAg) Status at Baseline
HBV e Antigen (HBeAg) Status at Baseline(participants)Tenofovir DFFTC/Tenofovir DFTotal
Negative7671147
Positive6568133
09

Study locations

71 sites
  • Bradenton, Florida 34205, United States
  • Flushing, New York 11355, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Innsbruck, A-6020, Austria
  • Wien, A-1090, Austria
  • Wien, A-1130, Austria
  • Sofia, 1407, Bulgaria
  • Sofia, 1527, Bulgaria
  • Sofia, 1606, Bulgaria
  • Varna, 9010, Bulgaria
  • Vancouver, British Columbia V5Z, Canada
  • Vancouver, British Columbia V6AB46, Canada
  • Vancouver, British Columbia V6Z 2K5, Canada
  • Winnepeg, Manitoba R3E 3P4, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Toronto, Ontario M5G 2C4, Canada
  • Toronto, Ontario M5T 2S8, Canada
  • Toronto, Ontario M6H 3M1, Canada
  • Brno, 625 00, Czech Republic
  • Plzen, 304 60, Czech Republic
  • Prague, 160 00, Czech Republic
  • Praha 4, 14021, Czech Republic
  • Usti Nad Labem, 40001, Czech Republic
  • Ulm, Baden-Wuerttemberg 89081, Germany
  • Berlin, 13353, Germany
  • Duesseldorf, 40225, Germany
  • Essen, 45122, Germany
  • Frankfurt, 60590, Germany
  • Hamburg, 20099, Germany
  • Hannover, 30625, Germany
  • Stuttgart, Germany
  • Larissa, 41110, Greece
  • Patras, 25404, Greece
  • Thessaloniki, 54642, Greece
  • Budapest, 1126, Hungary
  • Debrecen, 4032, Hungary
  • Gyula, H5700, Hungary
  • Kasposvar, H7400, Hungary
  • Auckland, New Zealand
  • Hamilton, New Zealand
  • Wellington, 6035, New Zealand
  • Bialystok, 15-540, Poland
  • Bydgoszcz, 85-030, Poland
  • Chorzow, 41-500, Poland
  • Krakow, 31-351, Poland
  • Lodz, 91-347, Poland
  • Szczecin, 71-455, Poland
  • Warszawa, 01-201, Poland
  • Warszawa, 02-507, Poland
  • Wroclaw, 50-220, Poland
  • Lasi, Judetul lasi 700111, Romania
  • Timisoara, Judetul Timis 300736, Romania
  • Bucharest, 021105, Romania
  • Bucharest, 022328, Romania
  • Bucharest, 030303, Romania
  • Bucuresti, 020125, Romania
  • Bucuresti, 021105, Romania
  • Bucuresti, 022328, Romania
  • Cluj-Napoca, 400158, Romania
  • Constanta, 900708, Romania
  • Belgrade, 11000, Serbia
  • Kragujevac, 34000, Serbia
  • Nis, 18000, Serbia
  • Novi Sad, 21000, Serbia
  • Sevilla, 4103, Spain
  • Ankara, 06100, Turkey
  • Bursa, 16059, Turkey
  • Izmir, 35100, Turkey
  • Samsun, 55139, Turkey
  • Trabzon, 61080, Turkey
  • Uskudar, 34668, Turkey
10

References and documents

Publications

  • Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2106-12.e1. doi: 10.1016/j.cgh.2014.05.024. Epub 2014 Jun 11. PubMed 24929235 ↗
  • Liu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, Miller MD, Kitrinos KM. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol. 2014 Sep;86(9):1473-81. doi: 10.1002/jmv.23982. Epub 2014 May 23. PubMed 24861361 ↗
  • Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014 Apr;146(4):980-8. doi: 10.1053/j.gastro.2013.12.028. Epub 2013 Dec 22. PubMed 24368224 ↗
  • Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee LJ, Elkhashab M, Berg T, Sporea I, Yurdaydin C, Husa P, Jablkowski MS, Gane E. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017 Jan;66(1):11-18. doi: 10.1016/j.jhep.2016.08.008. Epub 2016 Aug 18. PubMed 27545497 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Nov 2011 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2008
First posted
Aug 19, 2008
Start
Sep 2008
Primary completionActual
Nov 2011
CompletionActual
Feb 2015
Results first posted
Apr 11, 2013
Last update
Mar 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00737568
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 19, 2008
Start date
Sep 2008
Primary completion
Nov 2011
Completion
Feb 2015
Results posted
Apr 11, 2013
Last update
Mar 11, 2016

Study contacts

John Flaherty, PharmD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion